Jason West, MD
Family Medicine · Harrisburg, ILNPI 1760831218
Payments from drug & device makers
Across 110 payments — averaging $17.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$283
- AbbVie$271
- Lilly USA, LLC$261
- Dexcom, Inc.$122
- Novo Nordisk$119
- Otsuka America Pharmaceutical, Inc.$116
- plus $719 from 21 others
What the payments were for
- Food & beverage$1,892100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $283 |
| AbbVie | 18 | $271 |
| Lilly USA, LLC | 17 | $261 |
| Dexcom, Inc. | 5 | $122 |
| Novo Nordisk | 6 | $119 |
| Otsuka America Pharmaceutical, Inc. | 5 | $116 |
| Lundbeck LLC | 4 | $85 |
| GSK | 5 | $84 |
| Pfizer | 4 | $64 |
| Phathom Pharmaceuticals, Inc. | 5 | $62 |
| Verona Pharma, Inc. | 3 | $54 |
| Exact Sciences | 3 | $51 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| Novartis | 2 | $39 |
| Seqirus USA Inc | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
| Braeburn Inc. | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Vertex | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Abbott | 1 | $14 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $9 |
How this compares
$1,892 in reported general payments places this provider in the 80th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 144 | $144,996 |
| EliquisApixaban | 142 | $110,882 |
| OzempicSemaglutide | 95 | $92,995 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 134 | $86,625 |
| MounjaroTirzepatide | 39 | $38,689 |
| TrulicityDulaglutide | 24 | $34,522 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 66 | $30,696 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 221 | $28,638 |
| JanuviaSitagliptin Phosphate | 36 | $26,608 |
| Spiriva HandihalerTiotropium Bromide | 44 | $25,539 |
| FarxigaDapagliflozin Propanediol | 23 | $22,182 |
| LinzessLinaclotide | 22 | $17,917 |
| XareltoRivaroxaban | 22 | $17,177 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 20 | $16,755 |
| VascepaIcosapent Ethyl | 31 | $15,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $14 | $150,590155 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta, Shingrix | $84 | $146,340285 claims |
| PfizerEliquis | $64 | $110,882142 claims |
| Novo NordiskOzempic | $119 | $92,99595 claims |
| Lilly USA, LLCMounjaro, Trulicity | $261 | $73,21163 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $283 | $39,36373 claims |
| AbbVieLinzess | $271 | $17,91722 claims |
| Johnson & JohnsonXarelto | $20 | $17,17722 claims |
| NovartisEntresto | $39 | $13,42421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Harrisburg
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.